Source: The Wall Street Journal Valeant Pharmaceuticals International Inc. cut its annual outlook again Tuesday as the drug company, struggling to remake its business after a series of missteps, signaled its turnaround may take longer than expected. Shares of the company tumbled 25% to $14.42, the stock’s lowest point in…...